Does the media prefer DNA or TWST?

In the previous week, Twist Bioscience had 20 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 31 mentions for Twist Bioscience and 11 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.37 beat Twist Bioscience's score of 0.36 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 6 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, MEDP or TWST?

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.52 $451.12M $17.06 34.62 Twist Bioscience $431.80M 16.80 -$77.67M -$2.22 N/A

Is MEDP or TWST more profitable?

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Twist Bioscience -31.66% -28.64% -19.94%

Does the media favor MEDP or TWST?

In the previous week, Twist Bioscience had 24 more articles in the media than Medpace. MarketBeat recorded 31 mentions for Twist Bioscience and 7 mentions for Medpace. Medpace's average media sentiment score of 1.25 beat Twist Bioscience's score of 0.36 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 6 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, RVTY or TWST?

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.91B 4.40 $241.20M $2.10 54.67 Twist Bioscience $431.80M 16.80 -$77.67M -$2.22 N/A

Does the media favor RVTY or TWST?

In the previous week, Twist Bioscience had 10 more articles in the media than Revvity. MarketBeat recorded 31 mentions for Twist Bioscience and 21 mentions for Revvity. Revvity's average media sentiment score of 0.85 beat Twist Bioscience's score of 0.36 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 7 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 6 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TWST or ICLR?

Icon has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $431.80M 16.80 -$77.67M -$2.22 N/A Icon $8.29B 1.52 $229.34M $4.26 38.62

Is TWST or ICLR more profitable?

Icon has a net margin of 3.99% compared to Twist Bioscience's net margin of -31.66%. Icon's return on equity of 8.02% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -31.66% -28.64% -19.94% Icon 3.99% 8.02% 4.56%

Does the media favor TWST or ICLR?

In the previous week, Twist Bioscience had 21 more articles in the media than Icon. MarketBeat recorded 31 mentions for Twist Bioscience and 10 mentions for Icon. Icon's average media sentiment score of 1.05 beat Twist Bioscience's score of 0.36 indicating that Icon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 6 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Icon 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, TECH or TWST?

Bio-Techne has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.28 $73.40M $0.69 104.77 Twist Bioscience $431.80M 16.80 -$77.67M -$2.22 N/A

Does the media prefer TECH or TWST?

In the previous week, Twist Bioscience had 25 more articles in the media than Bio-Techne. MarketBeat recorded 31 mentions for Twist Bioscience and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.37 beat Twist Bioscience's score of 0.36 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 6 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Twist Bioscience (TWST) Competitors

$115.67 +6.59 (+6.04%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$114.06 -1.61 (-1.39%)

As of 08/7/2026 07:52 PM Eastern

Compare

TWST vs. DNA, MEDP, RVTY, ICLR, and TECH

Should you buy Twist Bioscience stock or one of its competitors? MarketBeat compares Twist Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Twist Bioscience include Ginkgo Bioworks (DNA), Medpace (MEDP), Revvity (RVTY), Icon (ICLR), and Bio-Techne (TECH). These companies are all part of the "life sciences tools & services" industry.

How does Twist Bioscience compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Ginkgo Bioworks has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Ginkgo Bioworks presently has a consensus target price of $7.00, suggesting a potential downside of 12.01%. Twist Bioscience has a consensus target price of $98.30, suggesting a potential downside of 15.02%. Given Ginkgo Bioworks' higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Twist Bioscience had 20 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 31 mentions for Twist Bioscience and 11 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.37 beat Twist Bioscience's score of 0.36 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	6 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$132.42M	3.92	-$312.76M	-$5.01	N/A
Twist Bioscience	$431.80M	16.80	-$77.67M	-$2.22	N/A

Summary

Twist Bioscience beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Medpace?

Medpace (NASDAQ:MEDP) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.52	$451.12M	$17.06	34.62
Twist Bioscience	$431.80M	16.80	-$77.67M	-$2.22	N/A

Medpace presently has a consensus price target of $584.18, suggesting a potential downside of 1.10%. Twist Bioscience has a consensus price target of $98.30, suggesting a potential downside of 15.02%. Given Medpace's higher probable upside, equities analysts plainly believe Medpace is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

78.0% of Medpace shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Twist Bioscience	-31.66%	-28.64%	-19.94%

In the previous week, Twist Bioscience had 24 more articles in the media than Medpace. MarketBeat recorded 31 mentions for Twist Bioscience and 7 mentions for Medpace. Medpace's average media sentiment score of 1.25 beat Twist Bioscience's score of 0.36 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	6 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Medpace beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Revvity?

Revvity (NYSE:RVTY) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

In the previous week, Twist Bioscience had 10 more articles in the media than Revvity. MarketBeat recorded 31 mentions for Twist Bioscience and 21 mentions for Revvity. Revvity's average media sentiment score of 0.85 beat Twist Bioscience's score of 0.36 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	7 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	6 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

86.7% of Revvity shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.91B	4.40	$241.20M	$2.10	54.67
Twist Bioscience	$431.80M	16.80	-$77.67M	-$2.22	N/A

Revvity has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Revvity has a net margin of 8.16% compared to Twist Bioscience's net margin of -31.66%. Revvity's return on equity of 8.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Revvity presently has a consensus target price of $108.36, indicating a potential downside of 5.61%. Twist Bioscience has a consensus target price of $98.30, indicating a potential downside of 15.02%. Given Revvity's higher probable upside, equities research analysts plainly believe Revvity is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Revvity beats Twist Bioscience on 10 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Icon?

Twist Bioscience (NASDAQ:TWST) and Icon (NASDAQ:ICLR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Twist Bioscience presently has a consensus price target of $98.30, indicating a potential downside of 15.02%. Icon has a consensus price target of $170.40, indicating a potential upside of 3.58%. Given Icon's higher possible upside, analysts clearly believe Icon is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41

Twist Bioscience has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Icon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Icon has a net margin of 3.99% compared to Twist Bioscience's net margin of -31.66%. Icon's return on equity of 8.02% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Icon	3.99%	8.02%	4.56%

In the previous week, Twist Bioscience had 21 more articles in the media than Icon. MarketBeat recorded 31 mentions for Twist Bioscience and 10 mentions for Icon. Icon's average media sentiment score of 1.05 beat Twist Bioscience's score of 0.36 indicating that Icon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	6 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Icon	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Icon has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	16.80	-$77.67M	-$2.22	N/A
Icon	$8.29B	1.52	$229.34M	$4.26	38.62

95.6% of Icon shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Icon beats Twist Bioscience on 12 of the 17 factors compared between the two stocks.

How does Twist Bioscience compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bio-Techne currently has a consensus price target of $68.08, indicating a potential downside of 5.83%. Twist Bioscience has a consensus price target of $98.30, indicating a potential downside of 15.02%. Given Bio-Techne's higher probable upside, equities research analysts plainly believe Bio-Techne is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Bio-Techne has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.28	$73.40M	$0.69	104.77
Twist Bioscience	$431.80M	16.80	-$77.67M	-$2.22	N/A

Bio-Techne has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

In the previous week, Twist Bioscience had 25 more articles in the media than Bio-Techne. MarketBeat recorded 31 mentions for Twist Bioscience and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.37 beat Twist Bioscience's score of 0.36 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	6 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bio-Techne has a net margin of 9.05% compared to Twist Bioscience's net margin of -31.66%. Bio-Techne's return on equity of 13.57% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Summary

Bio-Techne beats Twist Bioscience on 10 of the 16 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.25B	$9.57B	$7.01B	$13.00B
Dividend Yield	N/A	1.46%	2.58%	10.20%
P/E Ratio	-52.10	63.07	271.11	25.19
Price / Sales	16.80	263.54	597.74	81.69
Price / Cash	N/A	26.16	71.81	50.72
Price / Book	16.27	38.45	13.25	6.22
Net Income	-$77.67M	$56.66B	$3.45B	$342.66M
7 Day Performance	26.35%	5.17%	4.67%	4.41%
1 Month Performance	23.49%	0.37%	-1.28%	-1.11%
1 Year Performance	351.13%	22.07%	77.33%	23.99%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	1.4474 of 5 stars	$115.67 +6.0%	$98.30 -15.0%	+351.1%	$7.25B	$431.80M	N/A	990	News Coverage Earnings Report Analyst Forecast
DNA Ginkgo Bioworks	0.733 of 5 stars	$8.92 +10.2%	$8.50 -4.7%	-34.9%	$528.47M	$170.15M	N/A	640	News Coverage Earnings Report Analyst Downgrade
MEDP Medpace	2.6585 of 5 stars	$573.29 -0.7%	$584.18 +1.9%	+36.0%	$16.11B	$2.53B	33.60	6,200	Positive News
RVTY Revvity	2.8312 of 5 stars	$115.21 +2.4%	$108.36 -5.9%	+32.0%	$12.55B	$2.86B	55.12	11,000	Earnings Report Dividend Announcement Analyst Upgrade
ICLR Icon	3.2156 of 5 stars	$158.41 -3.2%	$170.40 +7.6%	+3.8%	$12.52B	$8.25B	37.19	40,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. DNA, MEDP, RVTY, ICLR, and TECH

How does Twist Bioscience compare to Ginkgo Bioworks?

Summary

How does Twist Bioscience compare to Medpace?

Summary

How does Twist Bioscience compare to Revvity?

Summary

How does Twist Bioscience compare to Icon?

Summary

How does Twist Bioscience compare to Bio-Techne?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. DNA, MEDP, RVTY, ICLR, and TECH

How does Twist Bioscience compare to Ginkgo Bioworks?

Which has more risk & volatility, DNA or TWST?

Do insiders and institutionals hold more shares of DNA or TWST?

Is DNA or TWST more profitable?

Do analysts prefer DNA or TWST?

Does the media prefer DNA or TWST?

Which has stronger earnings and valuation, DNA or TWST?

Summary

How does Twist Bioscience compare to Medpace?

Which has better valuation and earnings, MEDP or TWST?

Do analysts rate MEDP or TWST?

Which has more volatility and risk, MEDP or TWST?

Do insiders and institutionals have more ownership in MEDP or TWST?

Is MEDP or TWST more profitable?

Does the media favor MEDP or TWST?

Summary

How does Twist Bioscience compare to Revvity?

Does the media favor RVTY or TWST?

Do institutionals and insiders believe in RVTY or TWST?

Which has preferable valuation and earnings, RVTY or TWST?

Which has more volatility & risk, RVTY or TWST?

Is RVTY or TWST more profitable?

Do analysts rate RVTY or TWST?

Summary

How does Twist Bioscience compare to Icon?

Do analysts recommend TWST or ICLR?

Which has more risk and volatility, TWST or ICLR?

Is TWST or ICLR more profitable?

Does the media favor TWST or ICLR?

Which has stronger earnings & valuation, TWST or ICLR?

Do insiders and institutionals believe in TWST or ICLR?

Summary

How does Twist Bioscience compare to Bio-Techne?

Do institutionals and insiders believe in TECH or TWST?

Do analysts recommend TECH or TWST?

Which has stronger valuation and earnings, TECH or TWST?

Which has more volatility & risk, TECH or TWST?

Does the media prefer TECH or TWST?

Is TECH or TWST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools